ABS-201

ABS-201
Clinical data
Other namesABS201
Routes of
administration		Subcutaneous injection[1]
Drug classProlactin receptor monoclonal antibody
ATC code
  • None

ABS-201 is an AI-designed monoclonal antibody against the prolactin receptor (PRLR) currently in Phase 1/2a clinical trial[2][3][4] for the treatment of androgenic alopecia (pattern hair loss) and endometriosis.[1][5][6][7] It is taken by subcutaneous injection.[1][6] ABS-201 is a possible first-in-class drug with a novel mechanism of action in the potential treatment of hair loss.[8] ABS-201 is under development by Absci.[9][10]

It is believed that ABS-201 works by activating dormant hair follicles and causing them to move from the telogen phase to the anagen phase.[6][7] In human ex vivo scalp model studies, ABS-201 stimulated hair regrowth, prolonged anagen phase, blocked catagen phase, inhibited telogen effluvium, and blocked hair from losing color.[11][12] ABS-201 has been found to produce robust hair regrowth as compared with minoxidil in mice and balding macaques.[6][7]

The clinical trial for ABS-201 is being overseen by prominent hair loss researcher Rodney Sinclair,[6] one of the principal investigators in minoxidil clinical trials.[13][14] The chemical structure of the drug does not yet appear to have been disclosed.[1]

See also

References

  1. ^ a b c d "ABS 201". AdisInsight. 7 October 2025. Retrieved 14 November 2025.
  2. ^ Absci Pty Ltd. (2025-12-30). A Randomized, Double-Blind, Placebo-Controlled, Phase 1 First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ABS-201 in Healthy Adult Participants With and Without Androgenetic Alopecia (Report). clinicaltrials.gov.
  3. ^ "ABS 201 - Absci - AdisInsight". adisinsight.springer.com. Retrieved 2026-02-05.
  4. ^ "Absci Initiates First-in-Human Trial of AI-Designed Antibody ABS-201 for Hair Loss Treatment". MedPath. 2025-12-04. Retrieved 2026-02-05.
  5. ^ "Delving into the Latest Updates on ABS-201(Absci Corp) with Synapse". Synapse. 25 October 2025. Retrieved 14 November 2025.
  6. ^ a b c d e Frederickson E (20 October 2025). "A New Hair Loss Drug Could Cure Balding and Reverse Graying". Popular Mechanics. Retrieved 14 November 2025.
  7. ^ a b c Kahn A (2024). "Absci 2024 R&D Day Presentation". Absci Corporation.
  8. ^ "Absci Initiates First-in-Human Trial of AI-Designed Antibody ABS-201 for Hair Loss Treatment". MedPath. 2025-12-04. Retrieved 2026-02-05.
  9. ^ "ABS 201 - Absci - AdisInsight". adisinsight.springer.com. Retrieved 2026-02-05.
  10. ^ "Delving into the Latest Updates on ABS-201(Absci Corp) with Synapse". synapse.patsnap.com. Retrieved 2026-02-05.
  11. ^ "ABS-201 KOL SEMINAR". Absci. December 12, 2025.
  12. ^ "ABS 201 - Absci - AdisInsight". adisinsight.springer.com. Retrieved 2026-02-05.
  13. ^ Applied Biology, Inc. (2018-10-04). Minoxidil Response Testing in Females With Female Pattern Hair Loss (Report). clinicaltrials.gov.
  14. ^ "A 32-week randomized, placebo-controlled, double-blinded pilot study to compare the efficacy and safety of low-dose oral minoxidil in male and female patients with patterned hair loss (androgenetic alopecia) followed by a 24-week open label extension period". MedPath. 2021-11-15. Retrieved 2026-02-05.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.